Celcuity Inc. (CELC) is in Healthcare, Biotechnology, based in United States, listed on NasdaqCM. Market cap 3.32B USD. 52-week range 45.03 to 151.02 USD. Data as of 2026-10-09.
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 ...